XASE · Healthcare · Medical Devices
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on diagnostics and monitoring.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-14 | Q1 2026 | -0.73 | -0.97 | -32.88% | $985,076 | ❌ Miss | +3.64% | +22.73% | — |
| 2026-03-31 | Q4 2025 | -0.04 | -0.05 | -25.00% | $447,034 | ❌ Miss | -3.22% | -16.88% | -35.15% |
| 2025-11-13 |
| Q3 2025 |
| -0.05 |
| -0.05 |
| +0.00% |
| $627,277 |
| ➖ Inline |
| — |
| — |
| — |
| 2025-08-14 | Q2 2025 | -0.05 | -0.06 | -20.00% | $406,688 | mixed | -6.77% | +5.78% | +1.91% |
| 2025-03-31 | Q4 2024 | -0.05 | -0.06 | -20.00% | $191,657 | ❌ Miss | -9.03% | -12.31% | -15.80% |
| 2024-11-14 | Q3 2024 | -0.07 | -0.07 | +0.00% | $474,522 | ➖ Inline | -5.56% | +12.64% | -13.75% |
| 2024-08-14 | Q2 2024 | -0.09 | -0.08 | +11.11% | $395,797 | ✅ Beat | +3.19% | +23.10% | +23.03% |
| 2024-05-13 | Q1 2024 | -0.11 | -0.10 | +9.09% | $171,535 | ✅ Beat | -14.53% | -14.86% | -21.07% |
Showing last 8 quarters.